The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.
Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.
While chimeric antigen receptor (CAR) T-cell therapy has demonstrated its ability to produce responses in refractory tumors, many challenges remain with the therapies. Precision’s Phil Cyr discusses some of these challenges as well as questions and research that remain to be answered.
Read the full article here!
Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).
Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.
There is a big need for therapeutic advancement in the rare disease community – however, public markets are stifling innovation and development for advanced medicines. This webinar, on Thursday, September 15th, will examine the current markets, their effect on the innovation in rare disease drug development, and what we can do to help.
Sponsored by Precision ADVANCE, this panel features insights from industry leaders on their organization’s pipeline, the advanced therapy investment landscape, and the innovation, manufacturing, and community needs to successfully bring an advanced therapy to market. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Alex Karnal (Founder, Braidwell), Chidozie Ugwumba (Managing Partner, Symbiosis), James Wilson (Director, Perelman School of Medicine, UPenn), and Tony Khoury (EVP, Project Farma).
Key points to be discussed:
Precision will be at this year’s CAR-TCR summit on September 19-22, 2022, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for CAR and TCR therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
—
Ambassador Reception and Panel Discussion: Predictions for CAR-T Therapeutic Development
Precision ADVANCE | September 19, 2022, 6 – 8PM ET | Room 300, Hynes Convention Centre
Presentation: Understand the Nuances and Avoid Common Challenges in Cell Therapy Trial Execution
Precision for Medicine | September 20, 2022, 4:45-5:15PM EST
Presenter:
Panel Discussion: Building Next-Gen Commercial Cell Therapy Facilities
Project Farma | September 22, 2022, 9:00 – 9:30AM ET
Speakers:
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development, and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.